Difficulty: Medium
Average Score: 93%
Practice
The healthcare provider should anticipate that the most likely medication to be prescribed prophylactically for a child with spina bifida (myelomeningocele) who has a neurogenic bladder would be:
Correct answer
B
Rationale
The correct answer is B) Sulfisoxazole. In children with spina bifida (myelomeningocele) and neurogenic bladder, there is a risk of developing urinary tract infections (UTIs) due to incomplete bladder emptying. Sulfisoxazole is a sulfonamide antibiotic commonly used for UTI prophylaxis in this population. It works by inhibiting the growth of bacteria in the urinary tract, reducing the risk of UTIs.
Option A) Prednisone is a corticosteroid used for its anti-inflammatory properties and would not be the first choice for UTI prophylaxis in this case.
Option C) Furosemide (Lasix) is a diuretic used to treat fluid retention and edema by increasing urine output. It is not indicated for UTI prophylaxis.
Option D) Intravenous immune globulin (IVIG) is used to boost the immune system in certain conditions but is not indicated for UTI prophylaxis in children with neurogenic bladder.
Educationally, understanding the rationale behind selecting the appropriate medication for UTI prophylaxis in children with spina bifida and neurogenic bladder is crucial for providing safe and effective care to this vulnerable population. It highlights the importance of tailoring medication therapy to individual patient needs based on their underlying condition and associated risks.
Option A) Prednisone is a corticosteroid used for its anti-inflammatory properties and would not be the first choice for UTI prophylaxis in this case.
Option C) Furosemide (Lasix) is a diuretic used to treat fluid retention and edema by increasing urine output. It is not indicated for UTI prophylaxis.
Option D) Intravenous immune globulin (IVIG) is used to boost the immune system in certain conditions but is not indicated for UTI prophylaxis in children with neurogenic bladder.
Educationally, understanding the rationale behind selecting the appropriate medication for UTI prophylaxis in children with spina bifida and neurogenic bladder is crucial for providing safe and effective care to this vulnerable population. It highlights the importance of tailoring medication therapy to individual patient needs based on their underlying condition and associated risks.